• Explore /
  • Poster
  • / Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.

Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.

Abstract Poster

Authors

Evan Yu

Evan Y. Yu

University of Washington, Seattle, WA

Evan Y. Yu , Anthony M. Joshua , Gero Kramer , Neal D. Shore , Haixia Hu , Christian Heinrich Poehlein , Charles Schloss , Johann S. De Bono

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02861573

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS249)

DOI

10.1200/JCO.2024.42.4_suppl.TPS249

Abstract #

TPS249

Poster Bd #

Q10

Abstract Disclosures

Similar Posters

First Author: Johann S. De Bono

First Author: Gero Kramer

First Author: Peter C.C. Fong

First Author: Daniel Peter Petrylak